Riskpilot← Back to searchSign inGet full accessFOCUS PHARMA AS
ASActiveOrg 984583621Oredalsveien 134, 1613 FredrikstadWholesale of pharmaceutical and medical goods · NACE 4646Est. 20021 employees
Revenue 2024
NOK 1,3M
+11% vs 2023
EBITDA margin
9.9%
-57% vs 2023
Equity ratio
-104.0%
Financial strength
Net profit 2024
NOK 50K
+103% vs 2023
| Revenue | NOK 1,3M | +11% |
| EBITDA | NOK 124K | -57% |
| Net profit | NOK 50K | +103% |
| Total assets | NOK 689K | +21% |
| Equity | NOK -717K | +7% |
| Employees | 1 | — |
Legal name
FOCUS PHARMA AS
Org number
984583621
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10. juni 2002
Share capital
NOK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Import, kjøp og salg av farmasøytiske produkter samt alt som står i forbindelse med dette.
Address
Oredalsveien 134, 1613 Fredrikstad
Email
focusppltd@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 19 | 38 | 46 | 23 | 28 | 0 | 10 | 759 | 793 | 1 739 | 1 255 | 1 308 | 1 881 | 1 632 | 134 | 1 133 | 1 254 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −185 | −258 | −572 | −700 | −749 | −1 137 | −1 106 | −12 | −446 | −669 |
| EBITDA | 0 | −11 | 7 | 14 | −14 | −5 | −27 | −16 | 357 | 52 | 86 | −52 | −15 | 316 | 222 | −73 | 290 | 124 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | −11 | 7 | 14 | −14 | −5 | −27 | −16 | 357 | 52 | 86 | −52 | −15 | 316 | 222 | −73 | 290 | 124 |
| Net financials | 0 | −7 | −3 | −3 | −3 | −4 | −4 | −4 | −2 | −0 | 0 | −0 | 142 | 3 | −3 | −25 | −1 700 | −59 |
| Profit before tax | 0 | −18 | 4 | 12 | −17 | −9 | −31 | −20 | 355 | 52 | 86 | −52 | 126 | 318 | 218 | −98 | −1 410 | 65 |
| Tax | −0 | −5 | 1 | 3 | 56 | −0 | −0 | −0 | 22 | 13 | 21 | −0 | −0 | 54 | 48 | −0 | 42 | 14 |
| Net profit | 0 | −13 | 3 | 8 | −73 | −9 | −31 | −20 | 333 | 39 | 66 | −52 | 126 | 264 | 170 | −98 | −1 452 | 50 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | 114 | 120 | 134 | 60 | 54 | 26 | 10 | 364 | 349 | 568 | 682 | 828 | 999 | 1 808 | 2 353 | 571 | 689 |
| Equity | — | −41 | −38 | −29 | −102 | −111 | −142 | −163 | 171 | 209 | 275 | 223 | 349 | 613 | 784 | 685 | −767 | −717 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 154 | 158 | 163 | 162 | 165 | 168 | 173 | 193 | 140 | 293 | 459 | 479 | 386 | 1 024 | 1 668 | 1 338 | 1 406 |
| Total debt | 0 | 154 | 158 | 163 | 162 | 165 | 168 | 173 | 193 | 140 | 293 | 459 | 479 | 386 | 1 024 | 1 668 | 1 338 | 1 406 |
EBITDA margin
9.9%
This company
15.8%
Market median
-37% vs market
20072024
Equity ratio
-104.0%
This company
38.2%
Market median
-372% vs market
20072024
Return on equity
5032100.0%
This company
18.4%
Market median
+27348270% vs market
20072024
Net profit margin
4.0%
This company
8.1%
Market median
-51% vs market
20072024
Asset turnover
1.82×
This company
1.12×
Market median
+62% vs market
20072024
Debt / equity
1.96×
This company
0.62×
Market median
-216% vs market
20072024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BE Chief Executive Officer | Chief Executive Officer | 2002 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 67.0% | 67.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FOCUS PHARMA AS 
Forever Holding AsBoard members of FOCUS PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bjørn Erik Bergseng | Chief Executive Officer | 0 companies |
| Heidi Engebretsen Bergseng | Chairman | 0 companies |